Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 2, 2017

Cristal studies CriPec-docetaxel in Phase Ib oncology programme

Netherlands-based Cristal Therapeutics has launched a Phase Ib clinical programme to assess its nanomedicine candidate CriPec-docetaxel for the treatment of solid tumours. 

Netherlands-based Cristal Therapeutics has launched a Phase Ib clinical programme to assess its nanomedicine candidate CriPec-docetaxel for the treatment of solid tumours.

CriPec-docetaxel is being developed as a new drug modality to entrap a clinically validated chemotherapy, docetaxel (Taxotere), as therapeutic payload into nanoparticles.

Designed to allow increased tumour accumulation and local release of the drug, the candidate is intended to enhance therapeutic efficacy and overcome challenges such as toxic systemic side-effects associated with existing docetaxel products.

In addition to evaluation of the distribution and uptake of the nanomedicine candidate, Phase Ib programme will determine an optimal frequency and dosing schedule for Phase II clinical efficacy trials.

Cristal Therapeutics CEO and co-founder Dr Joost Holthuis said: “Progressing CriPec-docetaxel to a Phase Ib programme is an important milestone, and highlights the unique preliminary safety and pharmacokinetic data produced from the Phase Ia study.

“This highlights the unique preliminary safety and pharmacokinetic data produced from the Phase Ia study.”

“We look forward to the results of the consolidated Phase I programme.”

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

The preliminary positive data obtained from the open-label, safety and pharmacokinetic Phase Ia trial indicated favourable safety and tolerability of the nanomedicine.

Furthermore, the results revealed that CriPec-docetaxel could be given at therapeutic dose levels.

In addition, the nanomedicine candidate is reported to have shown improved pharmacokinetic profile, when compared with other docetaxel-based drug products such as Taxotere.

The Phase 1b programme is being performed at three clinical sites across the Netherlands and at the University Hospitals Leuven General Medical Oncology department in Belgium.

 

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU